Melanoma Associated with the Use of Melanotan-II

Hjuler, Kasper Fjellhaugen; Lorentzen, Henrik

doi:10.1159/000356389

Cited by 25 publications

(14 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25 Four cases have been reported in which melanoma arose from existing moles either during or shortly after the use of melanotan (Table 2). 31,35,37,38 Three of these patients used melanotan II, 31,37,38 and one used melanotan I. 35 This female also frequently visited tanning salons and had no family history of melanoma.…”

Section: Risks Of Unregulated Usementioning

confidence: 94%

“…Four cases have been reported in which melanoma arose from existing moles either during or shortly after the use of melanotan (Table ) . Three of these patients used melanotan II, and one used melanotan I . A 23‐year‐old female with type 2 skin developed itchiness and color alterations in an existing mole 2 weeks after using melanotan II.…”

Section: Risks Of Unregulated Usementioning

confidence: 99%

“…Histopathology revealed a melanoma with a Breslow thickness of 0.32 mm. This female also frequently visited tanning salons and had no family history of melanoma …”

Section: Risks Of Unregulated Usementioning

confidence: 99%

“…35 This female also frequently visited tanning salons and had no family history of melanoma. 37 A 43-year-old woman developed multiple new moles and exhibited growth/darkening of existing moles after using melanotan II. Her dosage schedule consisted of 2 days of 100 mg a day followed by 5 days of 50 mg a day (for a total of 450 mg a week).…”

Section: Risks Of Unregulated Usementioning

confidence: 99%

See 3 more Smart Citations

Risks of unregulated use of alpha‐melanocyte‐stimulating hormone analogues: a review

Habbema¹,

Halk

Neumann

et al. 2017

Int J Dermatology

View full text Add to dashboard Cite

Recently, the unregulated use of untested synthetic alpha-melanocyte-stimulating hormone (α-MSH) analogues, commonly known as melanotan I and II, appears to have increased. These analogues are primarily used for their tan-stimulating effects. Dermatologists see many patients in their clinic who tan. This review provides an overview of the risks of the unregulated use of these substances. Other topics discussed here include the history and safety of afamelanotide, which is the only α-MSH analogue that is approved for use in a limited number of medical indications. Although afamelanotide has been thoroughly tested and deemed safe, illegal melanotans are likely risky for several reasons. There are questions regarding the preparation, administration, and dosage of these substances. In addition to these general risks, increasing numbers of case reports indicate that the unregulated use of both melanotan I and II is associated with cutaneous complications, particularly melanocytic changes in existing moles and newly emerging (dysplastic) nevi. Four case reports have described melanomas emerging from existing moles either during or shortly after the use of melanotan. Although conclusive evidence linking these phenomena is lacking, publications have stressed the importance of awareness that melanotan is a part of a 'tanning culture' in certain subpopulations. Multiple national health organizations have issued safety warnings regarding the use of melanotan I and II.

show abstract

Section: Risks Of Unregulated Usementioning

confidence: 94%

Section: Risks Of Unregulated Usementioning

confidence: 99%

“…Histopathology revealed a melanoma with a Breslow thickness of 0.32 mm. This female also frequently visited tanning salons and had no family history of melanoma …”

Section: Risks Of Unregulated Usementioning

confidence: 99%

Section: Risks Of Unregulated Usementioning

confidence: 99%

See 2 more Smart Citations

Risks of unregulated use of alpha‐melanocyte‐stimulating hormone analogues: a review

Habbema¹,

Halk

Neumann

et al. 2017

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…Single studies and meta‐analyses have provided further evidence that there is an attributable risk for skin cancer due to sunbed use . The risk of melanoma related to sunbed use in 18 European countries was calculated to be about 3400 additional melanoma cases .…”

Section: Introductionmentioning

confidence: 99%

Decreasing sunbed use in the German population between 2001 and 2015: survey in 155 679 working persons

Augustin

Schäfer

Reusch

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background UV radiation is a proven cause of skin cancer. Use of sunbeds has been shown to provide an attributable risk. Objective To evaluate the proportion of regular sunbed use in Germany based on large‐scale population‐based surveys over 15 years. Methods Skin cancer screenings by dermatologists were conducted between 2001 and 2015 in more than 500 German companies, including a clinical examination and interviews on the risk behaviour related to sunburns and sunbeds. Results Among 155 679 persons included regular sunbed use significantly declined from 11.0% in 2001 to 1.6% in 2015 (P < 0.001). There were significantly higher rates of sunbed use in women (12.5%/2.0%) vs. men (7.3%/1.3%; P < 0.001), in younger persons and in participants with darker skin (type II and III) vs. fair skin (type I). Individuals with sunburns in childhood were significantly more often sunbed users (5.1% vs. 4.6%; P = 0.002). A remarkable decline of sunbed use was observed after 2009 (7.0% in 2001–2008 and 2.2% in 2009–2015). This reduction occurred in the time of a legal ban of sunbed use for minors but also with the start of the national skin cancer screening programme. Conclusion Use of sunbeds in the German adult population has dropped by more than 85% in the past decade. Primary prevention, including the large public awareness following the legal ban of sunbed use for young people and the effects of the statutory skin cancer screening programme may have contributed to this.

show abstract

The Skin and Endocrine Disorders

Paus

2016

Rook's Textbook of Dermatology, Ninth Edition

View full text Add to dashboard Cite

Given that the skin is a major target organ of numerous hormones for which it expresses functional receptors, it is not surprising that excessive or insufficient systemic levels of these hormones induce clinically relevant cutaneous responses. These can manifest as general skin symptoms and signs such as pruritus, skin dryness, seborrhoea, hair loss, hypertrichosis, hirsutism, hyperhidrosis and/or hyperpigmentation, any of which prompts consideration of an underlying endocrine disease. In addition, characteristic skin lesions such as palmar erythema, gingival hyperpigmentation, stretch marks (striae distensae), acanthosis nigricans, pretibial myxoedema, necrobiosis lipoidica, melasma and acneform eruptions provide invaluable diagnostic clues to the possibility of unrecognized endocrine disease. More recently, the field has been revolutionized by the recognition that human skin is also a major endocrine and neuroendocrine organ which produces and/or metabolizes not only all classes of steroid hormones but also multiple peptide (neuro‐) hormones, neuropeptides and neurotransmitters. These impact profoundly on skin physiology and pathology at multiple levels, ranging from skin barrier function and neurogenic skin inflammation via wound healing to cutaneous stress responses. This has important implications for future dermatological therapy.

show abstract

Melanoma Associated with the Use of Melanotan-II

Cited by 25 publications

References 12 publications

Risks of unregulated use of alpha‐melanocyte‐stimulating hormone analogues: a review

Risks of unregulated use of alpha‐melanocyte‐stimulating hormone analogues: a review

Decreasing sunbed use in the German population between 2001 and 2015: survey in 155 679 working persons

The Skin and Endocrine Disorders

Contact Info

Product

Resources

About